Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation

Pediatric Blood and Cancer

Volumn 57, Issue 4, 2011, Pages 660-665

  Sung, Ki Woong ^a   Park, Jun Eun ^b   Chueh, Hee Won ^a   Lee, Soo Hyun ^a   Yoo, Keon Hee ^a   Koo, Hong Hoe ^a   Kim, Ju Youn ^a   Cho, Eun Joo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Allogeneic stem cell transplantation; Graft versus tumor effect; Haploidentical stem cell transplantation; Neuroblastoma; Reduced intensity conditioning

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOLINIC ACID; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CHILDHOOD CANCER; CHIMERA; CLINICAL ARTICLE; DISEASE SEVERITY; FEASIBILITY STUDY; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEUROBLASTOMA; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79961188207     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23035     Document Type: Article

References (34)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173.
2. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005;6:649-658.
3. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006;24:2891-2896.
4. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18:2567-2575.
5. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II Study. J Clin Oncol 2002;20:2284-2292.
6. Sung KW, Lee SH, Yoo KH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 2007;40:37-45.
7. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 1999;17:3221-3225.
8. London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2010;28:3808-3815.
9. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130-2135.
10. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-389.
11. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004;103:435-441.
12. Inoue M, Nakano T, Yoneda A, et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003;32:103-106.
13. Lang P, Pfeiffer M, Müller I, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: Preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006;218:321-326.
14. Marabelle A, Paillard C, Tchirkov A, et al. Graft-versus-tumour effect in refractory metastatic neuroblastoma. Bone Marrow Transplant 2007;39:809-810.
15. Hirayama M, Azuma E, Araki M, et al. Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma. Transplantation 2006;82:142-144.
16. Radich JP, Gooley T, Sanders JE, et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000;6:272-279.
17. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:121-127.
18. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997;20:859-863.
19. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
20. Ueno NT, Cheng YC, Rondón G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003;102:3829-3836.
21. Kanold J, Paillard C, Tchirkov A, et al. Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: Toward a neuroblastoma model. Bone Marrow Transplant 2008;42:S25-S30.
22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
23. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
24. Matthay KK, Kushner BH. Treatment of relapsed and refractory neuroblastoma. In: Cheung NK, Cohn SL, editors. Neuroblastoma. Berlin Heidelberg: Springer, Inc.; 2005. pp. 193-212.
25. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Children's Cancer Group. J Clin Oncol 1994;12:2382-2389.
26. Ladenstein R, Lasset C, Hartmann O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994;14:37-46.
27. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-2149.
28. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24:500-506.
29. Takahashi H, Manabe A, Aoyama C, et al. Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma. Pediatr Blood Cancer 2008;50:676-678.
30. Toporski J, Garkavij M, Tennvall J, et al. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant 2009;15:1077-1085.
31. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-1759.
32. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD-2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-1334.
33. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001;27:777-783.
34. Lang P, Handgretinger R. Haploidentical SCT in children: An update and future perspectives. Bone Marrow Transplant 2008;42:S54-S59.